Thrombocytosis in myelodysplastic and myelodysplastic/myeloproliferative syndromes

References

• Greenberg P L, Baer M R, Bennett J M, Bloomfield C D, De Castro C M, Deeg H J, et al. Myelodysplastic syndromes clinical practice guidelines in oncology. J Natl Compr Canc Netw 2006; 4: 58–77
   PubMedGoogle Scholar
• Ma X, Does M, Raza A, Mayne S T. Myelodysplastic syndromes: incidence and survival in the United States. Cancer 2007; 109: 1536–1542
   PubMed Web of Science ®Google Scholar
• Vardiman J W, Harris N L, Brunning R D. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100: 2292–2302
   PubMed Web of Science ®Google Scholar
• Fukuhara T, Kakinoki Y. [Clinical features of a new category, myelodysplastic/myeloproliferative diseases, defined by WHO classification]. Rinsho Byori 2006; 54: 243–249
   PubMedGoogle Scholar
• Cabello A I, Collado R, Ruiz M A, Martinez J, Navarro I, Ferrer R, et al. A retrospective analysis of myelodysplastic syndromes with thrombocytosis: reclassification of the cases by WHO proposals. Leuk Res 2005; 29: 365–370
   PubMed Web of Science ®Google Scholar
• Perez Sanchez I, Perez Corrala A, Menarguez Palanca J, Mayayo Crespo M, Escudero Soto A, Pintado Cros T. Sideroblastic anaemia with reactive thrombocytosis versus myelodysplastic/myeloproliferative disease. Leuk Lymphoma 2003; 44: 557–559
   PubMed Web of Science ®Google Scholar
• Greenberg P, Cox C, LeBeau M M, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079–2088
   PubMed Web of Science ®Google Scholar
• Wang S A, Hasserjian R P, Loew J M, Sechman E V, Jones D, Hao S, et al. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis harbors JAK2 mutation and shows overlapping myeloproliferative and myelodysplastic features. Leukemia 2006; 20: 1641–1644
   PubMed Web of Science ®Google Scholar
• Schmitt-Graeff A, Thiele J, Zuk I, Kvasnicka H M. Essential thrombocythemia with ringed sideroblasts: a heterogeneous spectrum of diseases, but not a distinct entity. Haematologica 2002; 87: 392–399
   PubMed Web of Science ®Google Scholar
• Shaw G R. Ringed sideroblasts with thrombocytosis: an uncommon mixed myelodysplastic/myeloproliferative disease of older adults. Br J Haematol 2005; 131: 180–184
   PubMed Web of Science ®Google Scholar
• Szpurka H, Tiu R, Murugesan G, Aboudola S, Hsi E D, Theil K S, et al. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation. Blood 2006; 108: 2173–2181
   PubMed Web of Science ®Google Scholar
• Remacha A F, Nomdedeu J F, Puget G, Estivill C, Sarda M P, Canals C, et al. Occurrence of the JAK2 V617F mutation in the WHO provisional entity: myelodysplastic/myeloproliferative disease, unclassifiable-refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Haematologica 2006; 91: 719–720
   PubMed Web of Science ®Google Scholar
• Ceesay M M, Lea N C, Ingram W, Westwood N B, Gaken J, Mohamedali A, et al. The JAK2 V617F mutation is rare in RARS but common in RARS-T. Leukemia 2006; 11: 2060–2061
   Web of Science ®Google Scholar
• Steensma D P, Dewald G W, Lasho T L, Powell H L, McClure R F, Levine R L, et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both “atypical” myeloproliferative disorders and myelodysplastic syndromes. Blood 2005; 106: 1207–1209
   PubMed Web of Science ®Google Scholar
• Jelinek J, Oki Y, Gharibyan V, Bueso-Ramos C, Prchal J T, Verstovsek S, et al. JAK2 mutation 1849G > T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood 2005; 106: 3370–3373
   PubMed Web of Science ®Google Scholar
• Ohyashiki K, Aota Y, Akahane D, Gotoh A, Miyazawa K, Kimura Y, et al. The JAK2 V617F tyrosine kinase mutation in myelodysplastic syndromes (MDS) developing myelofibrosis indicates the myeloproliferative nature in a subset of MDS patients. Leukemia 2005; 19: 2359–2360
   PubMed Web of Science ®Google Scholar
• Germing U, Kundgen A, Gattermann N. Risk assessment in chronic myelomonocytic leukemia (CMML). Leuk Lymphoma 2004; 45: 1311–1318
   PubMed Web of Science ®Google Scholar
• Tefferi A, Elliott M A, Pardanani A. Atypical myeloproliferative disorders: diagnosis and management. Mayo Clin Proc 2006; 81: 553–563
   PubMed Web of Science ®Google Scholar
• Bowen D T. Chronic myelomonocytic leukemia: lost in classification?. Hematol Oncol 2005; 23: 26–33
   PubMed Web of Science ®Google Scholar
• Steensma D P, Tefferi A. Risk-based management of myelodysplastic syndrome. Oncology (Williston Park) 2007; 21: 43–54, discussion 57 – 58, 62
   PubMed Web of Science ®Google Scholar